ESC 365 - How might PCSK9 inhibition change this debate?

How might PCSK9 inhibition change this debate?

Session: New frontiers in cholesterol management in high cardiovascular risk patients

Topic: Primary cardiovascular prevention: interventions and outcomes

Speaker: Doctor S. Goodman (Toronto, CA)

Sponsored by Sanofi Regeneron

Event: ESC CONGRESS 2014

Add to my library

About the speaker

Doctor Shaun Goodman

St. Michael's Hospital, Toronto (Canada)

1 presentation

0 follower

5 more presentations in this session

Introduction - New frontiers in cholesterol management in high CV risk patients.

Speaker: Professor D. Bhatt (New York, US)

How low should LDL-C be lowered? All that matters is how you lower it.

Speaker: Doctor J. Robinson (Iowa, US)

How low should LDL-C be lowered? All that matters is how low you lower it.

Speaker: Professor K. Ray (London, GB)

Panel discussion - New frontiers in cholesterol management in high CV risk patients.

Concluding remarks - New frontiers in cholesterol management in high CV risk patients.

Speaker: Professor J. Zamorano Gomez (Madrid, ES)

Access the full session

New frontiers in cholesterol management in high cardiovascular risk patients

Speakers: Doctor S. Goodman, Professor D. Bhatt, Doctor J. Robinson, Professor K. Ray, Professor J. Zamorano Gomez

About the event

ESC CONGRESS 2014

30 August - 3 September 2014

Sessions Presentations

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources